Recall Alert: Bayer Pharmaceuticals Corp has at the request of the U.S. Food & Drug Administration (FDA) suspended sales of its antibleeding drug Trasylol, amid growing evidence that the drug may be linked to a higher risk of death than that of competing drugs.
Trasylol use has been linked to increased risk of death, kidney or renal failure, heart attacks, strokes and encephalopathy among heart surgery patients.
Breaking News: Feb. 17, 2008 — “One Thousand Lives A Month”
Feb. 17, 2008 — CBS 60 minutes video titled, “One Thousand Lives A Month” Researcher Estimates 22,000 Lives Could Have Been Saved Had Trasylol Been Pulled Earlier
U.S. Food & Drug Administration (FDA) Trasylol Recall Video
Trasylol Lawsuit Update: On May 14, 2008, Bayer Pharmaceuticals notified the U.S. Food & Drug Administration (FDA) that they would be initiating a nationwide Trasylol recall.
Read the Full Transcript: Marketing of Trasylol Suspended
Schmidt & Clark has been actively pursuing Trasylol side effect cases since 2006. The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Trasylol lawsuits. We are handling individual litigation nationwide and currently accepting new Trasylol cases in all 50 states.
FDA Announces Suspension of Trasylol
November 5, 2007 –The U.S. Food and Drug Administration (FDA) today announced that, at the agency’s request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.
What is Trasylol?
Trasylol (Generic: aprotinin) is an injectable prescription drug which inhibits certain enzymes that increase the risk of bleeding during surgery and aids the body’s ability to prevent bleeding.
Normally, the drug is given to patients undergoing heart bypass surgery to control blood loss, but has also been used in other surgeries, such as hip replacement surgery.
Trasylol is manufactured by Bayer Pharmaceuticals Corporation and was approved by the Food and Drug Administration in December 1993 to reduce bleeding and the need for blood transfusion in patients undergoing heart surgery.